Hosted on MSN1mon
Ionis stock rises on FDA, EMA nod for SMA drug dose increase
Biogen Inc. (NASDAQ:BIIB), which licensed the rights to nusinersen from Ionis Pharmaceuticals, stated that the new regimen could offer meaningful benefits to patients. The higher dose comprises ...
Hosted on MSN1y
Sheffield NHS: First patient to get new atrophy treatment “can walk for the pleasure of walking” again
It can create problems with swallowing, breathing, and moving the arms and legs, but nusinersen - the first ever approved ...
Nature3y
The expanding frontier of nucleic acid therapeutics
For example, Biogen’s nusinersen, an ASO therapy for the fatal neuromuscular condition spinal muscular atrophy (SMA), can reduce by half the likelihood of death or the need for mechanical ...